BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 2020;27:18. [PMID: 31906949 DOI: 10.1186/s12929-019-0609-7] [Cited by in Crossref: 132] [Cited by in F6Publishing: 123] [Article Influence: 66.0] [Reference Citation Analysis]
3 Brotschi C, Roch C, Gatfield J, Treiber A, Williams JT, Sifferlen T, Heidmann B, Jenck F, Bolli MH, Boss C. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep‐Promoting Properties in Rats. ChemMedChem 2019;14:1257-70. [DOI: 10.1002/cmdc.201900242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Schilling U, Henrich A, Muehlan C, Krause A, Dingemanse J, Ufer M. Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis. Clin Drug Investig 2021;41:711-21. [PMID: 34331678 DOI: 10.1007/s40261-021-01062-1] [Reference Citation Analysis]
5 Kim HJJ, Zagzoog A, Smolyakova AM, Ezeaka UC, Benko MJ, Holt T, Laprairie RB. In vivo Evidence for Brain Region-Specific Molecular Interactions Between Cannabinoid and Orexin Receptors. Front Neurosci 2021;15:790546. [PMID: 34992518 DOI: 10.3389/fnins.2021.790546] [Reference Citation Analysis]
6 Sun YY, Wang Z, Zhou HY, Huang HC. Sleep-Wake Disorders in Alzheimer's Disease: A Review. ACS Chem Neurosci 2022. [PMID: 35507669 DOI: 10.1021/acschemneuro.2c00097] [Reference Citation Analysis]
7 Krystal AD, Prather AA. Sleep Pharmacogenetics: The Promise of Precision Medicine. Sleep Med Clin 2019;14:317-31. [PMID: 31375201 DOI: 10.1016/j.jsmc.2019.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
8 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
9 Riemann D. Old and new methods in sleep research/sleep medicine and insomnia. J Sleep Res 2019;28:e12840. [PMID: 30834669 DOI: 10.1111/jsr.12840] [Reference Citation Analysis]
10 Cacabelos R. Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia. Int J Mol Sci 2020;21:E3059. [PMID: 32357528 DOI: 10.3390/ijms21093059] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Al-Kuraishy HM, Abdulhadi MH, Hussien NR, Al-Niemi MS, Rasheed HA, Al-Gareeb AI. Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review. Brain Circ 2020;6:70-80. [PMID: 33033776 DOI: 10.4103/bc.bc_42_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
12 Beydoun HA, Beydoun MA, Weiss J, Hossain S, Huang S, Alemu BT, Zonderman AB. Insomnia as a predictor of diagnosed memory problems: 2006-2016 Health and Retirement Study. Sleep Med 2021;80:158-66. [PMID: 33601227 DOI: 10.1016/j.sleep.2021.01.038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Uslaner JM, Herring WJ, Coleman PJ. The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts. ACS Pharmacol Transl Sci 2020;3:161-8. [PMID: 32259095 DOI: 10.1021/acsptsci.9b00110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Skillman B, Kerrigan S. CYP450-Mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens. Forensic Sci Int 2020;312:110307. [PMID: 32473525 DOI: 10.1016/j.forsciint.2020.110307] [Reference Citation Analysis]
15 Guyenet PG, Stornetta RL, Souza GMPR, Abbott SBG, Brooks VL. Neuronal Networks in Hypertension: Recent Advances. Hypertension 2020;76:300-11. [PMID: 32594802 DOI: 10.1161/HYPERTENSIONAHA.120.14521] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 Greenwald MK, Moses TEH, Roehrs TA. At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities. Transl Res 2021;234:58-73. [PMID: 33711513 DOI: 10.1016/j.trsl.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Clark JW, Brian ML, Drummond SP, Hoyer D, Jacobson LH. Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Sleep Medicine Reviews 2020;53:101332. [DOI: 10.1016/j.smrv.2020.101332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]